Story perspectives

TransMedics and Core Scientific Stocks Surge Amid Growth

9/12/2025

Summary

Story summary

TransMedics Group Inc. stock increased by 9.84% amid positive sentiment for its organ transplant solutions.
Analysts hold a neutral rating with a $115 price target, while the average target is $142.89.
The company reported Q2 2025 revenue of $157M, surpassing expectations despite some gross margin pressure.
Core Scientific Inc. stock rose by 7.6% due to strategic advancements and a partnership with NVIDIA.
Core Scientific's Q2 revenue reached $78.6M, indicating growth in high-performance computing.

History

Historical Context

In 2001, the U.S. government established the Organ Procurement and Transplantation Network to improve organ transplant efficiency. This initiative reflects a broader trend in medical advancements, as seen in TransMedics Group Inc.'s reported Q2 2025 revenue of $157 million, driven by innovations in healthcare technology and strategic partnerships, indicating a promising future for organ transplant solutions.

1 of 2

Story summary

TransMedics Group Inc. stock increased by 9.84% amid positive sentiment for its organ transplant solutions.
Analysts hold a neutral rating with a $115 price target, while the average target is $142.89.
The company reported Q2 2025 revenue of $157M, surpassing expectations despite some gross margin pressure.
Core Scientific Inc. stock rose by 7.6% due to strategic advancements and a partnership with NVIDIA.
Core Scientific's Q2 revenue reached $78.6M, indicating growth in high-performance computing.

1 / 2